Gain Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

GANX$1.08-0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets (Unaudited)

CONDENSED CONSOLIDATED BALANCE SHEETS


· · · June 30, · · December 31,
· · · 2026 · · 2025
Assets · · · ·
Current assets: · · · ·
Cash and cash equivalents	$13,084,144	$20,837,628
Tax credits	210,494	179,701
Prepaid expenses and other current assets	1,675,110	1,219,809
Total current assets	14,969,748	22,237,138

Noncurrent assets:
Property and equipment, net	47,026	74,916
Internal-use software, net	76,782	102,837
Operating lease right-of-use assets	266,861	334,090
Restricted cash	35,589	36,296
Long-term deposits and other noncurrent assets	25,933	33,698
Total noncurrent assets	452,191	581,837
Total assets	$15,421,939	$22,818,975

Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$1,220,365	$825,027
Operating lease liabilities - current	109,428	119,876
Other current liabilities	1,980,444	2,306,624
Loans - current	123,628	100,869
Total current liabilities	3,433,865	3,352,396

Noncurrent liabilities:
Defined benefit pension plan	319,225	390,509
Operating lease liabilities - noncurrent	156,760	211,238
Loans - noncurrent	220,058	300,084
Total noncurrent liabilities	696,043	901,831
Total liabilities	$4,129,908	$4,254,227

Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	$—	$—
Common stock, $0.0001 par value: 100,000,000 shares authorized; 43,340,501 and 42,073,807 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	4,335	4,209
Additional paid-in capital	121,924,254	119,139,677
Accumulated other comprehensive income	1,003,752	776,869
Accumulated deficit	(111,640,310)	(101,356,007)
Total stockholders’ equity	11,292,031	18,564,748
Total liabilities and stockholders’ equity	$15,421,939	$22,818,975

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.